Barnett Gibbs
Cardiovascular Disease · Richmond, VANPI 1679634869
Payments from drug & device makers
Across 110 payments — averaging $112.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$10K
- E.r. Squibb & Sons, L.L.C.$193
- Boston Scientific$175
- Abbott$166
- Novo Nordisk$134
- Actelion Pharmaceuticals US, Inc.$117
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$2,25046%
- Food & beverage$2,51852%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $10,255 |
| E.r. Squibb & Sons, L.L.C. | 6 | $193 |
| Boston Scientific | 7 | $175 |
| Abbott | 3 | $166 |
| Novo Nordisk | 6 | $134 |
| Actelion Pharmaceuticals US, Inc. | 2 | $117 |
| Novartis | 5 | $101 |
| Irhythm Technologies, Inc. | 5 | $99 |
| Inspire Medical Systems, Inc. | 4 | $97 |
| Baxter Healthcare | 3 | $93 |
| AstraZeneca | 5 | $90 |
| Pfizer | 5 | $87 |
| Alnylam Pharmaceuticals Inc. | 4 | $80 |
| Atricure, Inc. | 2 | $65 |
| Bardy Diagnostics, Inc. | 5 | $63 |
| Boehringer Ingelheim | 3 | $60 |
| Philips North America LLC | 3 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Johnson & Johnson | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $41 |
| Impulse Dynamics (USA) Inc. | 2 | $39 |
| Cvrx, Inc. | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $22 |
| Heartflow, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Merck | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$2,375
- HeartMate 3 Left Ventricular Dev$129
How this compares
$12,363 in reported general payments places this provider in the 80th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 336 | $371,300 |
| XareltoRivaroxaban | 121 | $141,030 |
| EntrestoSacubitril/Valsartan | 46 | $55,843 |
| OzempicSemaglutide | 14 | $16,144 |
| Repatha SyringeEvolocumab | 16 | $13,797 |
| FarxigaDapagliflozin Propanediol | 13 | $12,226 |
| BrilintaTicagrelor | 16 | $12,045 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 27 | $6,678 |
| Nebivolol Hcl | 45 | $3,379 |
| Metoprolol Succinate | 215 | $2,938 |
| Dofetilide | 34 | $2,876 |
| Amiodarone Hcl | 33 | $2,596 |
| Amlodipine Besylate | 324 | $2,190 |
| Valsartan | 82 | $2,131 |
| Losartan Potassium | 155 | $1,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $371,300336 claims |
| Johnson & JohnsonXarelto | $45 | $141,030121 claims |
| NovartisEntresto | $101 | $55,84346 claims |
| AstraZenecaFarxiga, Brilinta | $90 | $24,27129 claims |
| Novo NordiskOzempic | $134 | $16,14414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Richmond
- George VetrovecRichmond$2.3M
- Anurag MehtaRichmond$492K
- Gautham KalahastyRichmond$150K
- Mary Ann PeberdyRichmond$83K
- Roshanak MarkleyRichmond$68K
- Tariq HaddadFalls Church$8M
- David LimCharlottesville$6M
- Hamid TaheriManassas$4.9M
- Philip OdonnellWinchester$4.6M
- Antonio AbbateCharlottesville$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.